Compare FTAI Aviation Ltd (FTAI) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FTAI Aviation Ltd vs Viatris Inc — how do they compare? FTAI Aviation Ltd trades at $201.57 (market cap $21.93B), while Viatris Inc trades at $17.23 (market cap $19.44B). The key difference: FTAI Aviation Ltd and Viatris Inc are close in size by market cap, and Viatris Inc pays the higher dividend (2.88%). Which is the better fit depends on your goals.
| FTAI | VTRS | |
|---|---|---|
Market Cap | $21.93B | $19.44B |
Sector | Industrials | Health |
52-Week High | $310.04 | $17.39 |
52-Week Low | $109.92 | $8.74 |
Enterprise Value | $24.97B | $31.65B |
Dividend Yield | 0.7% | 2.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FTAI Aviation trades at $205.71, down 0.25% with a bearish technical outlook despite unanimous analyst buy ratings. The company reported strong revenue growth to $2.51 billion in 2025 with 19% net margins, though recent quarters show earnings misses. Positive developments include a strategic Boeing 737-800 freighter collaboration and expansion into data center power solutions, while negative operating cash flow raises execution concerns.
The stock presents growth potential from aerospace servicing and new power segment opportunities, but faces risks from consistent earnings misses and high valuations (P/E 42.6). Institutional sentiment remains strongly positive with 100% buy ratings, though technical indicators suggest near-term pressure with support at $195.
Viatris (VTRS) trades at $17.215, up 5.55% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3 billion in 2025 but posted a net loss of $3.51 billion, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a decision expected by December 2026. Analyst consensus leans toward Hold, with a $20 price target suggesting modest upside from current levels.
The outlook for VTRS hinges on successful pipeline execution and debt management, offering value potential if biosimilar and specialty drug launches gain traction. Key risks include persistent negative margins, high debt levels, and competitive pressures in the generics market. Investors should weigh the company's cost-cutting efforts and product diversification against its profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About FTAI Aviation Ltd
FTAI Aviation owns and maintains a fleet of commercial aircraft and engines. It focuses on the specialized maintenance of the CFM56 engine, helping airlines reduce costs through efficient asset management.
Read more on FTAI →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
